Edition:
United States

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

224.55CHF
18 May 2018
Change (% chg)

CHF0.55 (+0.25%)
Prev Close
CHF224.00
Open
CHF224.00
Day's High
CHF225.80
Day's Low
CHF222.95
Volume
1,705,087
Avg. Vol
2,059,985
52-wk High
CHF269.50
52-wk Low
CHF212.45

Chart for

About

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas:... (more)

Overall

Beta: 0.94
Market Cap(Mil.): CHF193,933.20
Shares Outstanding(Mil.): 862.56
Dividend: 8.30
Yield (%): 3.70

Financials

  ROG.S Industry Sector
P/E (TTM): 22.37 28.57 32.53
EPS (TTM): 10.04 -- --
ROI: 17.02 13.08 12.63
ROE: 34.29 14.80 14.50

Roche says has had no contact with Trump lawyer Cohen

ZURICH Roche has had no contact with U.S. President Donald Trump's personal attorney Michael Cohen, the Swiss pharmaceuticals maker's Chief Executive said on Thursday.

May 17 2018

Roche says has had no contact with Trump lawyer Cohen

ZURICH, May 17 Roche has had no contact with U.S. President Donald Trump's personal attorney Michael Cohen, the Swiss pharmaceuticals maker's Chief Executive said on Thursday.

May 17 2018

Swiss stocks - Factors to watch on May 17

ZURICH, May 17 The Swiss blue-chip SMI was seen opening 0.2 percent higher at 8,988 points on Thursday, according to premarket indications by bank Julius Baer .

May 17 2018

Swiss stocks - Factors to watch on May 17

ZURICH, May 17 Here are some of the main factors that may affect Swiss stocks on Thursday:

May 17 2018

Roche immunotherapy combination increases lung cancer survival - study

Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage trial released on Wednesday.

May 16 2018

Roche immunotherapy combination increases lung cancer survival-study

May 16 Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage trial released on Wednesday.

May 16 2018

Swiss stocks - Factors to watch on May 16

ZURICH, May 16 The Swiss blue-chip SMI was seen opening 0.2 percent higher at 9,016 points on Wednesday, according to premarket indications by bank Julius Baer.

May 16 2018

BRIEF-FDA Approves Additional Claim For Roche Cobas Zika Test

* NEW CLAIM ALLOWS FOR STREAMLINED SCREENING OF POOLED BLOOD OR PLASMA DONATIONS Source text for Eikon: Further company coverage:

May 14 2018

BRIEF-Roche Holding AG CEO Says Very Confident We Can Grow In Spite Of The Entry Of Biosimilars

* CEO SAYS CONFIDENT OF ROCHE'S ABILITY TO CONTINUE GROWTH BEYOND 2018 DESPITE BIOSIMILAR ENTRIES

Apr 26 2018

BRIEF-Roche Expands Indication For Cobas EGFR Mutation Test V2 As Companion Diagnostic With Tagrisso

* ROCHE EXPANDS INDICATION FOR COBAS® EGFR MUTATION TEST V2 AS A COMPANION DIAGNOSTIC WITH TAGRISSO®

Apr 18 2018

Earnings vs. Estimates